Gilead Sciences's (NASDAQ:GILD) share price is 7.2% lower in the past 12 months and has underperformed the overall US TECH market which is 3.1% higher in the same timeframe. This means a -10.3% lower return over the period which puts the share price as an underperformer vs other US TECH companies.
From 28 analysts that cover Gilead Sciences's stock, the average rating is 3.5. This is a weighted average of 2 strong buys, 11 buys, 15 holds. This is 0.4 lower than a month ago which gives this factor a tea-score of 1/5.
Gilead Sciences insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 100.0% which is 99.0% higher than the last 12 months buy to sell ratio. This put's Gilead Sciences's Insiders in the top quintile vs their peers giving this factor a tea-score of 5/5.
For Gilead Sciences, currently 82.6% of stock (1 billion shares) is owned by Institutions, 16.7% (802 million shares) is owned by Individuals, and 0.7% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 3/5.
As of 31 July 2019, the short interest for Gilead Sciences has been 1.24% of the shares outstanding which is 157 billion shares. This is more than 1 month ago which had 0.95% of the shares outstanding which is 120 billion short interest in shares. This equals a tea-score of 4/5.
Gilead Sciences's revenue in the last 12 months ending 30 June 2019 is $22Bn. Gilead Sciences's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.
Gilead Sciences's free cash flow yield is 9.6% and has shrunk from 4 years ago. The free cash flow yield for Gilead Sciences 1 year ago was 13.1% and 3 years ago it was 17.6%.
Gilead Sciences pays dividends every 3 months and has done so since 02 April 2013. Dividends have been steadily increasing over the past 4 years from $0.43 (dividend yield of 0.44%) to $0.63 today (yield of 0.94%).
Gilead Sciences's PE ratio is 13.7x. This is calculated from their EPS of $2.02 and price per share of $63.14. Gilead Sciences's PE ratio values the company cheaper than 20% of it's competitors giving this factor a tea-score of 1/5.
Gilead Sciences's PEG ratio is 3.9x. This is calculated from their PE ratio of 13.7x and their last 12 months growth rate of 0.035%. This is more attractive than their competitors so the tea-score for this factor is 5/5.
The PB ratio for Gilead Sciences is 3.5x. This is cheaper than their competitors who have an average PB ratio of 5.5x. The tea-score is 2/5.
Gilead Sciences's free cash flow yield is 9.6% which is ranked 1.0/5 when compared to its competitors. This is calculated from a free cash flow of - (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $79Bn. The average free cash flow yield across Gilead Sciences's comps is 8.1%.
Gilead Sciences's return on investment is 26.7%. This is more profitable than its competitors.
Gilead Sciences's current ratio is calculated by (current assets) / (current liabilities) which equals 3.8x. This less attractive than their competitors and also worse than recommended for a healthy company.
Gilead Sciences's debt to shareholder equity is 117.1%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.
Gilead Sciences's dividend payout ratio calculated against their free cash flow is low at 54.0%. This is in quintile 3 when measured against their comps.
Gilead Sciences's has a good overall ESG rating of 62/100. Their competitors have a score between 38 and 79 with the average at 58.
What is the 52 week high for Gilead Sciences stock quote?
Gilead Sciences (NASDAQ:GILD) hit a new 52-week high on 03 October 2018 at a price of $76.86 with 6,560,100 shares traded that day. This is 21.7% higher than than its current price of $63.14 and 29.4% higher than the 52-week low of $59.39 on 24 December 2018. Average daily volume traded has been 6 million shares over the past 3 months.
What is the highest price Gilead Sciences stock has ever been?
The all-time highs for Gilead Sciences stock were reached on 03 October 2018, 320 days ago at a price of $76.86. This equates to a market capitalisation of $97Bn. The highest price reached is 21.7% higher than the current price of $63.14 with a current market cap of $79Bn.
What is the beta of Gilead Sciences stock?
Gilead Sciences stock moves 1.2x the US TECH market average which makes its beta higher than the overall market.
What is the volatility of Gilead Sciences (GILD) stock?
Gilead Sciences's stock has an annual volatility of 24.3% which is more volatile than the average US TECH market volatility of 20.8% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.
What have Gilead Sciences's share buybacks been over the past year?
Gilead Sciences is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 7.2% lower which is an underperformance of -10.3% vs the overall market. Gilead Sciences still has $420Trn of cash remaining on their balance sheet.
Who owns the most Gilead Sciences stock?
Barry White is the largest individual shareholder in Gilead Sciences with 1 billion shares. He is an independent director of Gilead Sciences. The largest institutional holder is T-Rowe and they own 7.9% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.
When did Gilead Sciences beat earnings expectations in the last 4 years?
In the past 4 quarters Gilead Sciences has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.
When is Gilead Sciences's next earnings date and what are the expectations?
Gilead Sciences is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.
What is Gilead Sciences's upcoming earnings report expectations?
The earnings expectations for Gilead Sciences's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.
What is Gilead Sciences's earnings per share (EPS)?
Gilead Sciences's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82
What is Gilead Sciences's dividend growth rate?
Gilead Sciences's dividends have grown at 10.53% in the past year and an average growth of 11.63% over the past 4 years. This is higher then it's competitors 4-year average dividend growth of 4.1
What is Gilead Sciences's dividend yield?
Gilead Sciences's current dividend yield is 0.94%. This is calculated by taking the dividend's per share of $0.63 (the last payment which was on 13 June 2019) and dividing by the current share price of $63.14.
What is Gilead Sciences's previous and next dividend date?
Gilead Sciences's most recent dividend date was 13 June 2019 when the company paid $0.63 and the next dividend date is 12 September 2019 with an expected payment of $0.63.